Pterostilbene protects against acute renal ischemia reperfusion injury and inhibits oxidative stress, inducible nitric oxide synthase expression and inflammation in rats via the Toll‑like receptor 4/nuclear factor‑κB signaling pathway

Abstract

Abstract. Previous studies have demonstrated that pterostilbene (Pter) prevents oxidative stress, suppresses cell growth and exhibits anti-fungal and anti-inflammatory effects. Pter is used to treat a number of clinical diseases, including Alzheimer's disease, various malignancies and hypercholesteremia. The aim of the present study was to investigate whether Pter protects against acute renal ischemia reperfusion injury (IRI) and inhibits oxidative stress, inducible nitric oxide synthase (iNOS) expression and inflammation in rats. A total of 40 adult male Sprague Dawley rats were divided into the following 5 groups at random: Control group, where rats were not subjected to renal IRI; IRI group, where rats were subjected to renal IRI; Pter 10 group, where rats underwent renal IRI and were treated with 10 mg/kg Pter; Pter 20 group, where rats underwent renal IRI and were treated with 20 mg/kg Pter; Pter 30 group, where rats underwent renal IRI and were treated with 30 mg/kg Pter. The results demonstrated that Pter treatment improved renal function following acute renal IRI. Compared with the untreated renal IRI group, myeloperoxidase, iNOS, interleukin (IL)-1β, IL-6 and tumor necrosis factor-α expression levels were significantly decreased (P<0.01), whereas IL-10 expression levels were significantly increased (P<0.01) following treatment with Pter in acute renal IRI rats. In addition, Pter significantly attenuated caspase-3 activity and the Toll-like receptor 4 (TLR4)/nuclear factor (NF)-κB signaling pathway induced by acute renal IRI (P<0.01). These results provide evidence to suggest that administration of Pter may protect against acute renal IRI and inhibit oxidative stress, iNOS expression and inflammation in rats via the TLR4/NF-κB signaling pathway.

Pterostilbene Ameliorates Nephropathy Injury in Streptozotocin-Induced Diabetic Rats

“…A study also showed that PS inhibited the high fat-induced atherosclerosis inflammation via NF-κB signaling pathway [14]. Moreover, PS protected against acute renal ischemia reperfusion injury via the Toll-like receptor 4/NF-κB signaling pathway [15]. However, the effect of PS against DN has not been explored.…”

Evaluation of pheniramine maleate and zofenopril in reducing renal damage induced by unilateral ureter obstruction. An experimental study

“…In this aspect, the time period under obstruction is of critical importance. Antioxidant agents may be useful in order to protect kidney function and reserves until the extinction of the obstruction and after [23][24][25]. Planning of future studies including renal function tests may bring addition of antioxidants into first line treatment options in order to protect the functions of the hydronephrotic kidneys.…”

Pterostilbene administration improves the recovery potential of extremely low-frequency magnetic field in acute renal ischemia-reperfusion injury: An FTIR spectroscopic study

“…Acute renal ischemia-reperfusion (I/R) injury can be described as the damage occurring in ischemic renal cells after the reestablishment of the blood supply (Gao et al, 2018). Acute renal I/R injury is one of the pathological mechanisms underlying acute renal failure and is likely to occur following renal transplantation and septic shock (Gao et al, 2018). The pathophysiology of acute renal failure has been closely connected to tubular epithelial cell injury.…”

“…In recent studies, the use of Pte was reported to be beneficial in the treatment and prevention of myocardial (Yu et al, 2017), hindlimb (Cheng et al, 2016), and cerebral (Zhou et al, 2015) I/R injury. In addition, it was demonstrated to protect against acute renal ischemic injury by inhibiting oxidative stress and inflammation (Gao et al, 2018).…”

“…Consequently, Pte was previously demonstrated to diminish renal injury in I/R (Gao et al, 2018); however, the exact therapeutic potential of ELF-MF application for renal I/R injury is still not clear in the literature. In addition, the interaction of ELF-MF with other agents, such as cisplatin, to change its mode of action was previously reported in the literature (Bułdak et al, 2012).…”